A Landmark Milestone in Otology

Gene therapy has historically targeted systemic or ophthalmic conditions. However, the recent accelerated FDA approval of Otarmeni (lunsotogene parvec-cwha)—the first-ever gene therapy approved to treat severe-to-profound hearing loss associated with biallelic OTOF (otoferlin) gene mutations—has established a new paradigm in regenerative otology.

Data from pivotal clinical trials, including the CHORD study for Otarmeni and the AK-OTOF-101 trial developed by Eli Lilly/Akouos, have demonstrated historic efficacy. Children born with profound genetic deafness have had their physiological hearing restored, with significant portions of trial cohorts achieving normal hearing levels. While these clinical successes validate the therapeutic approach, translating these results into a scalable, global treatment model introduces severe operational and surgical bottlenecks.

The Surgical Hurdle: Intracochlear Delivery

Unlike systemic gene therapies delivered via standard intravenous infusion, therapeutics for genetic hearing loss require highly localised delivery:

• Microinjection via the Round Window: The AAV vector must be injected directly into the inner ear (cochlea) through the round window membrane. This requires a delicate microinjection procedure that must be executed with absolute precision to prevent mechanical damage to the cochlear structures.

• Global Surgeon Training: Scaling this therapy requires establishing global surgeon-training programmes. Otolaryngologists and ENT surgeons worldwide must be trained and certified on standardized injection devices, surgical protocols, and safety procedures.

• Paediatric Considerations: The target patient population consists of infants and young children (ideally treated before speech development). Performing delicate inner-ear microinjections on pediatric anatomy requires a high degree of specialised surgical skill.

The Manufacturing Complexity of Dual-AAV Vectors

From a CMC (Chemistry, Manufacturing, and Controls) perspective, OTOF gene therapies present a unique biological challenge. The otoferlin gene is too large (~6kb) to fit within the standard packaging capacity of a single adeno-associated virus (AAV) vector (~4.7kb).

To circumvent this limitation, developers utilise dual-AAV vector platforms. The gene is split into two halves, packaged into separate vectors, and co-delivered to the target inner hair cells, where they recombine to form the full-length otoferlin protein. Manufacturing two distinct vector batches under GMP conditions and ensuring equal co-transduction efficiency in vivo significantly increases CMC complexity and cost compared to single-vector platforms.

Sourcing Operations Leaders for Localised Delivery

Scaling these advanced therapeutics requires Clinical Operations Directors who have specific experience in localized delivery platforms (such as intraocular, intrathecal, or intracochlear delivery) rather than standard systemic therapies.

RSA prioritises several core competencies when sourcing operational leadership for advanced otology platforms:

• Surgical Network Scaling: Experience establishing global clinical trial networks, managing relationships with leading academic medical centres, and coordinating multi-site surgeon training and certification initiatives.

• Dual-Vector CMC Oversight: Sourcing manufacturing directors who can manage the production complexities of split-vector systems, ensuring consistency in vector ratios and product purity.

• Early Patient Identification Operations: Collaborating with medical affairs teams to establish early genetic screening programmes at birth, identifying candidates with biallelic OTOF variants before speech delays set in.

The clinical validation of hearing restoration is complete; the next phase is operational. Securing clinical operations leaders who can scale the delivery and surgical infrastructure is the primary requirement to transition these landmark therapies from clinical trials into standard global medical practice.